335 related articles for article (PubMed ID: 25263320)
1. Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine.
Duong VH; Bhatnagar B; Zandberg DP; Vannorsdall EJ; Tidwell ML; Chen Q; Baer MR
Leuk Lymphoma; 2015 Jun; 56(6):1718-22. PubMed ID: 25263320
[TBL] [Abstract][Full Text] [Related]
2. Clinical activity, pharmacokinetics, and pharmacodynamics of oral hypomethylating agents for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: A multidisciplinary review.
Haumschild R; Kennerly-Shah J; Barbarotta L; Zeidan AM
J Oncol Pharm Pract; 2024 Jun; 30(4):721-736. PubMed ID: 38509812
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine.
Jabbour E; Garcia-Manero G; Ravandi F; Faderl S; O'Brien S; Fullmer A; Cortes JE; Wierda W; Kantarjian H
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):131-8. PubMed ID: 23260600
[TBL] [Abstract][Full Text] [Related]
4. Retrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabine.
Jabbour E; Kantarjian H; O'Brien S; Kadia T; Malik A; Welch MA; Teng A; Cortes J; Ravandi F; Garcia-Manero G
Clin Lymphoma Myeloma Leuk; 2013 Oct; 13(5):592-6. PubMed ID: 23790798
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Value of Pretreatment Fetal Hemoglobin Levels in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia Treated with Azacitidine: A Single-center Retrospective Study.
Saga T; Kanagawa M; Harada T; Lang L; Yamawaki F; Ishihara T
Intern Med; 2024 Mar; 63(6):781-790. PubMed ID: 37495538
[TBL] [Abstract][Full Text] [Related]
6. Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen.
Ali AM; Weisel D; Gao F; Uy GL; Cashen AF; Jacoby MA; Wartman LD; Ghobadi A; Pusic I; Romee R; Fehniger TA; Stockerl-Goldstein KE; Vij R; Oh ST; Abboud CN; Schroeder MA; Westervelt P; DiPersio JF; Welch JS
Cancer Med; 2017 Dec; 6(12):2814-2821. PubMed ID: 29058375
[TBL] [Abstract][Full Text] [Related]
7. Factors Determining Responses to Azacitidine in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia with Early Post-Transplantation Relapse: A Prospective Trial.
Woo J; Deeg HJ; Storer B; Yeung C; Fang M; Mielcarek M; Scott BL
Biol Blood Marrow Transplant; 2017 Jan; 23(1):176-179. PubMed ID: 27789363
[TBL] [Abstract][Full Text] [Related]
8. The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes.
Jabbour E; Garcia-Manero G; Cornelison AM; Cortes JE; Ravandi F; Daver N; Kadia T; Teng A; Kantarjian H
Leuk Lymphoma; 2015 Feb; 56(2):390-4. PubMed ID: 24844364
[TBL] [Abstract][Full Text] [Related]
9. Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes.
Garcia-Manero G; Jabbour E; Borthakur G; Faderl S; Estrov Z; Yang H; Maddipoti S; Godley LA; Gabrail N; Berdeja JG; Nadeem A; Kassalow L; Kantarjian H
J Clin Oncol; 2013 Jul; 31(20):2548-53. PubMed ID: 23733767
[TBL] [Abstract][Full Text] [Related]
10. A prospective multicenter observational study of decitabine treatment in Korean patients with myelodysplastic syndrome.
Lee JH; Jang JH; Park J; Park S; Joo YD; Kim YK; Kim HG; Choi CW; Kim SH; Park SK; Park E; Min YH
Haematologica; 2011 Oct; 96(10):1441-7. PubMed ID: 21659363
[TBL] [Abstract][Full Text] [Related]
11. Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes.
Brunner AM; Esteve J; Porkka K; Knapper S; Traer E; Scholl S; Garcia-Manero G; Vey N; Wermke M; Janssen JJWM; Narayan R; Fleming S; Loo S; Tovar N; Kontro M; Ottmann OG; Naidu P; Sun H; Han M; White R; Zhang N; Mohammed A; Sabatos-Peyton CA; Steensma DP; Rinne ML; Borate UM; Wei AH
Am J Hematol; 2024 Feb; 99(2):E32-E36. PubMed ID: 37994196
[TBL] [Abstract][Full Text] [Related]
12. Azacitidine in Lower-Risk Myelodysplastic Syndromes: A Meta-Analysis of Data from Prospective Studies.
Komrokji R; Swern AS; Grinblatt D; Lyons RM; Tobiasson M; Silverman LR; Sayar H; Vij R; Fliss A; Tu N; Sugrue MM
Oncologist; 2018 Feb; 23(2):159-170. PubMed ID: 29118268
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of azacitidine in myelodysplastic syndromes.
Vigil CE; Martin-Santos T; Garcia-Manero G
Drug Des Devel Ther; 2010 Sep; 4():221-9. PubMed ID: 20957213
[TBL] [Abstract][Full Text] [Related]
14. 5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome--a systematic review and meta-analysis.
Gurion R; Vidal L; Gafter-Gvili A; Belnik Y; Yeshurun M; Raanani P; Shpilberg O
Haematologica; 2010 Feb; 95(2):303-10. PubMed ID: 19773261
[TBL] [Abstract][Full Text] [Related]
15. Decitabine can be safely reduced after achievement of best objective response in patients with myelodysplastic syndrome.
Ghanem H; Cornelison AM; Garcia-Manero G; Kantarjian H; Ravandi F; Kadia T; Cortes J; O'Brien S; Brandt M; Borthakur G; Jabbour E
Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2(0 2):S289-94. PubMed ID: 23969308
[TBL] [Abstract][Full Text] [Related]
16. Clinical status of induction therapy incorporating a hypomethylating agent for newly diagnosed adult acute myeloid leukemia compared to the standard 7+3 regimen.
Ohmoto A; Fuji S
Expert Rev Hematol; 2023; 16(10):761-771. PubMed ID: 37670667
[TBL] [Abstract][Full Text] [Related]
17. Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia.
Cogle CR; Scott BL; Boyd T; Garcia-Manero G
Oncologist; 2015 Dec; 20(12):1404-12. PubMed ID: 26463870
[TBL] [Abstract][Full Text] [Related]
18. Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications.
Pleyer L; Burgstaller S; Stauder R; Girschikofsky M; Sill H; Schlick K; Thaler J; Halter B; Machherndl-Spandl S; Zebisch A; Pichler A; Pfeilstöcker M; Autzinger EM; Lang A; Geissler K; Voskova D; Geissler D; Sperr WR; Hojas S; Rogulj IM; Andel J; Greil R
J Hematol Oncol; 2016 Apr; 9():39. PubMed ID: 27084507
[TBL] [Abstract][Full Text] [Related]
19. Demethylating agents in myeloid malignancies.
Garcia-Manero G
Curr Opin Oncol; 2008 Nov; 20(6):705-10. PubMed ID: 18841054
[TBL] [Abstract][Full Text] [Related]
20. A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents.
Short NJ; Muftuoglu M; Ong F; Nasr L; Macaron W; Montalban-Bravo G; Alvarado Y; Basyal M; Daver N; Dinardo CD; Borthakur G; Jain N; Ohanian M; Jabbour E; Issa GC; Qiao W; Huang X; Kanagal-Shamanna R; Patel KP; Bose P; Ravandi F; Delumpa R; Abramova R; Garcia-Manero G; Andreeff M; Cortes J; Kantarjian H
J Hematol Oncol; 2023 Jul; 16(1):73. PubMed ID: 37422688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
